🚀 VC round data is live in beta, check it out!
Stem Cells Spin Valuation Multiples
Discover revenue and EBITDA valuation multiples for Stem Cells Spin and similar public comparables like Hemp & Health, Rain Forest International, NUTEX, Enorama Pharma and more.
Stem Cells Spin Overview
About Stem Cells Spin
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
Founded
2009
HQ
Employees
3
Website
Financials (FY)
EV
$4M
Stem Cells Spin Financials
Stem Cells Spin reported last fiscal year revenue of $18K and EBITDA of $273K.
In the same fiscal year, Stem Cells Spin generated $13K in gross profit, $273K in EBITDA, and had net loss of ($140K).
Stem Cells Spin P&L
In the most recent fiscal year, Stem Cells Spin reported revenue of $18K and EBITDA of $273K.
Stem Cells Spin expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $18K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $13K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 75% | XXX | XXX | XXX |
| EBITDA | — | XXX | $273K | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 1536% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (787%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($140K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (788%) | XXX | XXX | XXX |
| Net Debt | — | — | $42K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Stem Cells Spin Stock Performance
Stem Cells Spin has current market cap of $4M, and enterprise value of $4M.
Market Cap Evolution
Stem Cells Spin's stock price is $0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $4M | 0.5% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStem Cells Spin Valuation Multiples
Stem Cells Spin trades at 247.7x EV/Revenue multiple, and 16.1x EV/EBITDA.
Stem Cells Spin Financial Valuation Multiples
As of April 8, 2026, Stem Cells Spin has market cap of $4M and EV of $4M.
Equity research analysts estimate Stem Cells Spin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stem Cells Spin has a P/E ratio of (31.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 247.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 16.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (31.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 330.1x | XXX | XXX | XXX |
| P/E | — | XXX | (31.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (189.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Stem Cells Spin Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Stem Cells Spin Margins & Growth Rates
Stem Cells Spin's revenue in the last fiscal year grew by 21%.
Stem Cells Spin's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.1M for the same period.
Stem Cells Spin Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 1536% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 3% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 862% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Stem Cells Spin Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hemp & Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Rain Forest International | XXX | XXX | XXX | XXX | XXX | XXX |
| NUTEX | XXX | XXX | XXX | XXX | XXX | XXX |
| Enorama Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Aqua Bio Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stem Cells Spin M&A Activity
Stem Cells Spin acquired XXX companies to date.
Last acquisition by Stem Cells Spin was on XXXXXXXX, XXXXX. Stem Cells Spin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Stem Cells Spin
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStem Cells Spin Investment Activity
Stem Cells Spin invested in XXX companies to date.
Stem Cells Spin made its latest investment on XXXXXXXX, XXXXX. Stem Cells Spin invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Stem Cells Spin
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Stem Cells Spin
| When was Stem Cells Spin founded? | Stem Cells Spin was founded in 2009. |
| Where is Stem Cells Spin headquartered? | Stem Cells Spin is headquartered in Poland. |
| How many employees does Stem Cells Spin have? | As of today, Stem Cells Spin has over 3 employees. |
| Is Stem Cells Spin publicly listed? | Yes, Stem Cells Spin is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Stem Cells Spin? | Stem Cells Spin trades under SCS ticker. |
| When did Stem Cells Spin go public? | Stem Cells Spin went public in 2011. |
| Who are competitors of Stem Cells Spin? | Stem Cells Spin main competitors are Hemp & Health, Rain Forest International, NUTEX, Enorama Pharma. |
| What is the current market cap of Stem Cells Spin? | Stem Cells Spin's current market cap is $4M. |
| What is the current revenue of Stem Cells Spin? | Stem Cells Spin's last fiscal year revenue is $18K. |
| What is the current EV/Revenue multiple of Stem Cells Spin? | Current revenue multiple of Stem Cells Spin is 247.7x. |
| Is Stem Cells Spin profitable? | No, Stem Cells Spin is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.